An observational study of molecular profIling of advanced and aggRessive ENdometrial cancer and 1-st line treatment approaches in Russian Federation

Trial Identifier: D0817R00117
Sponsor: AstraZeneca
Start Date: June 2025
Primary Completion Date: June 2027
Study Completion Date: June 2027
Condition: Endometriosis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russian Federation Arkhangelsk, Russian Federation
Russian Federation Barnaul, Russian Federation
Russian Federation Chelyabinsk, Russian Federation
Russian Federation Ekaterinburg, Russian Federation
Russian Federation Irkutsk, Russian Federation
Russian Federation Izhevsk, Russian Federation
Russian Federation Krasnodar, Russian Federation
Russian Federation Krasnoyarsk, Russian Federation
Russian Federation Moscow, Russian Federation
Russian Federation Saint Petersburg, Russian Federation
Russian Federation Severodvinsk, Russian Federation
Russian Federation Sochi, Russian Federation
Russian Federation Tomsk, Russian Federation
Russian Federation Ufa, Russian Federation
Russian Federation Vladivostok, Russian Federation
Russian Federation Yaroslavl, Russian Federation